Remdesivir Market Report 2026

The remdesivir market size has grown exponentially in recent years. It will grow from $8.52 billion in 2025 to $11.17 billion in 2026 at a compound annual growth rate (CAGR) of 31.2%. The growth in the historic period can be attributed to emergency use authorization of remdesivir, high hospitalization rates during COVID-19 peaks, limited antiviral treatment options, growing awareness of antiviral therapies, rapid scale-up of hospital procurement channels.

The remdesivir market size is expected to see rapid growth in the next few years. It will grow to $17.96 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to development of novel remdesivir formulations, increasing adoption of oral and ready-to-use injectable solutions, expansion of telemedicine-supported antiviral administration, rising government initiatives for COVID-19 management, growth in online pharmacy and home delivery services. Major trends in the forecast period include rising demand for intravenous antiviral therapies, increased adoption of oral antiviral formulations, growth in hospitalization and critical care treatments for COVID-19, expansion of online and retail pharmacy distribution channels, development of ready-to-use injectable and lyophilized powder solutions.

The growth in government expenditure is expected to support the expansion of the remdesivir market in the coming years. Government expenditure, also referred to as government spending, represents the total funds allocated and spent by governments or public sector bodies to finance operations, programs, services, and development initiatives. Government spending plays a key role in enhancing the availability and accessibility of remdesivir, particularly during public health emergencies. Through financial support, regulatory facilitation, bulk procurement, and investments in research, governments help ensure the affordability and supply of this essential antiviral drug. For example, in April 2025, according to the American Medical Association, a US-based professional organization, U.S. health spending increased by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per capita, surpassing the 4.6% growth recorded in 2022. As a result, rising government expenditure is contributing to the growth of the remdesivir market.

The increase in healthcare expenditure is also expected to drive the growth of the remdesivir market going forward. Healthcare expenditure refers to the total financial resources spent by individuals, institutions, or governments on the prevention, treatment, and management of health conditions. Healthcare spending continues to rise due to advancements in medical technologies, as innovative diagnostic tools, treatments, and therapies often involve higher costs, leading to increased overall healthcare budgets. Higher healthcare expenditure supports the adoption of remdesivir by enabling governments and healthcare facilities to secure adequate supplies, strengthen distribution systems, and provide timely treatment for COVID-19 patients, thereby improving patient access and clinical outcomes. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency overseeing Medicare and Medicaid programs, U.S. healthcare spending rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. Consequently, rising healthcare expenditure is fueling the growth of the remdesivir market.

The growing demand for clinical trials and research is further expected to propel the expansion of the remdesivir market. Clinical trials and research involve structured and systematic studies conducted in healthcare and medical sciences to assess the safety, effectiveness, and performance of drugs, treatments, medical devices, diagnostic tools, and healthcare interventions. Clinical trials play a critical role in evaluating the safety and efficacy of remdesivir in treating viral infections, including COVID-19. These studies generate scientific evidence supporting the drug’s ability to reduce disease severity and duration while establishing its safety profile. For example, in May 2023, according to Xtalks, a Canada-based digital health company, a total of 452,604 clinical studies were registered globally in 2023, with 64,838 actively recruiting participants. Therefore, the increasing emphasis on clinical trials and research is driving the growth of the remdesivir market.

Major companies operating in the remdesivir market are Gilead Sciences Inc., BrightGene Bio-Medical Technology Co Ltd, Hainan Haiyao Co. Ltd., Sichuan Kelun Pharmaceutical Co. Ltd., Hunan Warrant Pharmaceutical, Cipla Limited, Dr Reddy’s Laboratories Ltd., Shenzhen BORUI Pharmaceutical Technology Co. Ltd., Hetero Labs Limited, Mylan N.V., Zydus Cadila Health Care Limited, Syngene International Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Teva Pharmaceutical Industries, Ferozsons Laboratories Limited, Jubilant Life Sciences, Laurus Labs, Macleods Pharmaceuticals, Natco Pharma, Sandoz Group AG, Strides Pharma Science Limited, Torrent Pharmaceuticals, Beximco Pharmaceuticals Ltd., Fresenius Kabi, Gland Pharma Limited, Hikma Pharmaceuticals, Lark Laboratories.

North America was the largest region in the remdesivir market in 2025. Middle East is expected to be the fastest growing region in the remdesivir market report during the forecast period. The regions covered in the remdesivir market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the remdesivir market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the remdesivir market by increasing costs of imported active pharmaceutical ingredients, excipients, and packaging materials, affecting production and distribution. Intravenous formulations and lyophilized powders are most impacted, particularly in regions like North America and Europe that rely heavily on imports. While tariffs have raised treatment costs and slowed supply chains, they have also promoted local manufacturing, innovation in formulation technologies, and increased self-reliance in domestic production capacities.

The remdesivir market research report is one of a series of new reports that provides remdesivir market statistics, including remdesivir industry global market size, regional shares, competitors with a remdesivir market share, detailed remdesivir market segments, market trends and opportunities, and any further data you may need to thrive in the remdesivir industry. This remdesivir market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Remdesivir is an antiviral medication used to treat hospitalized adults and children aged 28 days and older who weigh at least 6.6 pounds (3 kg) for coronavirus disease 2019 (COVID-19), which is caused by the SARS-CoV-2 virus. It is administered to patients who are at high risk of progressing to severe COVID-19, a condition that may lead to hospitalization or death.

The primary routes of administration for remdesivir are oral and intravenous. Intravenous administration refers to the delivery of a drug or other substance directly into a vein through a syringe or tubing. The various dosage forms include tablets, frozen solutions, and lyophilized solutions, and these are distributed through multiple channels such as hospitals, clinics, drug stores or pharmacies, online platforms, and others.

The remdesivir market consists of sales of nucleotide analogue and Veklury. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.